AAN 2026 at a glance
The AAN Annual Meeting 2026 (AANAM 2026) will highlight developments across Alzheimer’s disease, epilepsy, migraine, Parkinson’s disease, multiple sclerosis and stroke, alongside AI applications that could influence clinical decision-making, patient management and treatment differentiation.
📅 Build your schedule around the topics that matter most.
📥 Download the AAN 2026_Preview_by_LucidQuest
AAN 2026: Key Developments in Neurology
Alzheimer’s Disease, Dementia and Cognitive Disorders
Alzheimer’s disease and dementia management is expected to broaden beyond amyloid, using biomarker-guided, stage-specific and symptom-targeted strategies.
Anti-Amyloid Therapy and ARIA Management
Lecanemab showed modest benefit, ALZ-NET reported ARIA-E of 5% and ARIA-H of 7%, and continued treatment may preserve slowing.
These findings highlight the importance of clinical benefit, safety monitoring and treatment management.
Epilepsy, Seizures and Sleep Disorders
Care is expected to expand beyond symptom control, prioritizing function, behavior, caregiver burden and high-need populations.
Headache and Migraine Treatment
Migraine care is projected to become more individualized, guided by cognition, comorbidities and real-world response variability.
Parkinson’s Disease and Neuromodulation
Parkinson’s care is expected to shift toward continuous delivery, earlier optimization and next-generation neuromodulation platforms.
Multiple Sclerosis and Neuroimmunology
Neuroimmunology is set to advance through novel immune targets, earlier intervention and function-focused long-term monitoring.
Stroke and Cerebrovascular Disorders
Stroke management is expected to depend on faster treatment, sharper etiologic classification, stronger prevention and better post-event care.
Artificial Intelligence and Machine Learning at AAN 2026
AI in Neurology: Clinical Triage and Diagnostic Support
Clarityv8 reached 96.0% sensitivity and 99.9% negative predictive value (NPV), while stroke virtual-assistant triage achieved 93.6% referral accuracy.
AI for Stroke Prognostication
ROS-ESUS reached AUROC 0.854/0.835, posterior-circulation acute ischemic stroke models achieved 89% accuracy, and rural triage achieved AUC 0.88.
Alzheimer’s Disease Digital Biomarkers
MyCog reached AUC 0.890, gait ensembles achieved AUC 0.93/0.89, and EEG denoising improved classification to AUROC 0.86.
Parkinson’s Disease Predictive Modeling
LSTM atrophy forecasting delivered five regional AUROCs above 0.9, with gait wearables reaching AUC 0.88.
AI in Epilepsy: Genetic Triage and EEG Analysis
Adult genetic epilepsy triage reached AUC 0.79, hybrid EEG exceeded 99% accuracy, but prospective-like validation remained limited.
Explainable AI and Clinical Trust
SHAP, feature reduction, omission-rate auditing and fairness-aware frameworks are expected to become core for adoption and clinician trust.
Operational AI in Neurology Practice
Practice-network data suggest 50–70% time savings, while AI scribes and translation tools raise safety and oversight questions.
Download the LucidQuest’s AANAM 2026 Preview Report
Download LucidQuest’s AANAM 2026 preview report and planner for insights into emerging neurology developments, AI applications and their competitive implications.
📅 Build your schedule around the sessions that matter most.
📥 Download the AAN 2026_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.
